Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian healthcare system;Evaluación económica del tratamiento de la esquizofrenia con antipsicóticos en Sistema Único de Salud

Revista de Saude Publica

Volumn 43, Issue SUPPL. 1, 2009, Pages 62-69

  Lindner, Leandro Mendonça ^a   Marasciulo, Antonio Carlos ^a   Farias, Mareni Rocha ^a   Grohs, Geder Evandro Motta ^b  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b Instituto de Psiquiatria   (Brazil)

Author keywords

Antipsychotic agents; Cost effectiveness evaluation; Health care costs quality adjusted life years; Schizophrenia; Single health system

Indexed keywords

BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; BRAZIL; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; HUMAN; PATIENT COMPLIANCE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENT DISEASE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAZIL; COST-BENEFIT ANALYSIS; DRUG COSTS; HALOPERIDOL; HUMANS; MARKOV CHAINS; MEDICATION ADHERENCE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; RISPERIDONE; SCHIZOPHRENIA;

EID: 77449120528     PISSN: 00348910     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0034-89102009000800010     Document Type: Article

References (17)

1. Almond S, O'Donnell O. Cost analysis of threatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics. 2000;17(4):383-9.
2. Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess. 2003;7(13):1-193.
3. Blatt CR, Farias MR. Diagnóstico do Programa de Medicamentos Excepcionais do Estado de Santa Catarina - Brasil. Lat Am J Pharm. 2007;26(5):776-83.
4. Bobes J, Cañas F, Rejas J, Mackel J. Economic consequences of the adverse reactions related whit antipsicotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(8):1287-97. DOI: 10.1016/j.pnpbp.2004.06.017
5. Briggs A, Sculpher M. An Introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397-409. DOI: 10.2165/00019053-199813040-00003
6. Cohen LJ. Suicide and schizophrenia: data from a prospective community treatment study. Am J Psychiatry. 1990;147(5):602-7.
7. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3. ed. London: Oxford Medical Publications; 2005.
8. Glennie JL. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1997. Technology overview: pharmaceuticals; 1-15.
9. Jayaram MB, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev. 2006;(2):CD005237. DOI: 10.1002/14651858.CD005237.pub2
10. Jorge MHPM, Koizumi MS. Gastos governamentais do SUS com internações hospitalares por causas externas: análise no Estado de São Paulo, 2000. Rev Bras Epidemiol. 2004;7(2):228-38. DOI: 10.1590/S1415-790X2004000200012
11. Knapp M, Simon J, Percudani M, Almond S. Economics of schizophrenia: a review. In: Maj M, Sartorius N (editors). WPA Series in Evidence-Based Psychiatry: Schizophrenia. 2. ed. Chichester: John Wiley and Sons; 2002. p.413-60.
12. Lecomte P, De Hert M, van Dijk M, Nuijten M, Nuyts G, Persson U. A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium. Value Health. 2000;3(1):1-11. DOI: 10.1046/j.1524-4733.2000.31001.x
13. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;61(2 Suppl):1-56.
14. Leitão RJ, Ferraz MB, Chaves AC, Mari JJ. Cost of schizophrenia: direct costs and use of resources in the State of São Paulo. Rev Saude Publica. 2006;40(2):304-9. DOI: 10.1590/S0034-89102006000200017
15. Palmer CS, Brunner E, Ruíz-Flores LG, Paes-Agraz F, Revicki DA. A cost-effectiveness clinical decision analysis model for treatment of schizophrenia. Arch Med Res. 2002;33(6):572-80. DOI: 10.1016/S0188-4409(02)00409-5
16. Palmer CS, Revicki DA, Gentuso LA, Hamilton SH, Brown, RE. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Manag Care. 1998;4(3):345-55.
17. Sacristán JA, Badia X, Rovira J. Farmacoeconomia: evaluacíon económica de medicamentos. Madrid: Editores Médicos; 1995.